Related Experiment Video

Updated: Jul 18, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Targeting BRAF in thyroid cancer

A V Espinosa1, L Porchia, M D Ringel

  • 1Divisions of Endocrinology and Oncology, Department of Medicine, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, OH, USA.

British Journal of Cancer
|December 21, 2006
PubMed

Insights

Activating BRAF mutations drive papillary thyroid cancer. Targeting BRAF offers a promising therapeutic strategy for aggressive thyroid cancers unresponsive to standard treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Activating BRAF mutations are prevalent oncogenic drivers in papillary thyroid cancer.
  • BRAF activation promotes malignant transformation and aggressive tumor phenotypes.
  • BRAF and RAF kinases mediate oncogenic effects like dedifferentiation and proliferation in thyroid cancer.

Purpose of the Study:

  • To review the role of BRAF activation in thyroid cancer development.
  • To evaluate the therapeutic potential of BRAF-targeted agents for thyroid cancer.

Main Methods:

  • Review of in vitro and in vivo experimental models.
  • Analysis of data on BRAF activation in thyroid cancer pathogenesis.
  • Assessment of clinical data for BRAF-targeted therapies.

Main Results:

  • BRAF activation is a key event in thyroid cancer initiation and progression.
  • BRAF signaling pathways are critical for tumor dedifferentiation and proliferation.
  • BRAF-targeted agents show potential efficacy in preclinical and clinical settings.

Conclusions:

  • BRAF is a significant oncogene in papillary thyroid cancer.
  • Targeting BRAF and its downstream pathways represents a viable therapeutic strategy.
  • BRAF-targeted therapies may offer new options for aggressive and refractory thyroid cancers.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...